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Purpose of the study
Lersivirine (LRV) is a next-generation NNRTI currently
under investigation in two Phase IIb studies at doses of
500 - 1000 mg QD. In vitro analyses suggest that LRV is
a weak Ikr and CA
2+ channel blocker. However, dose-
ranging Phase I studies have not shown prolongation of
QTc interval to date. This study was performed to
investigate the effect of a supratherapeutic dose of LRV
on QTc interval in healthy subjects, relative to matched
placebo and active control.
Methods
A randomized, single-dose, placebo- and active-con-
trolled 3-way crossover study was performed with 48
healthy adults. Subjects were randomized to receive
either LRV (2400 mg), moxifloxacin (400 mg) or placebo
for each treatment period with minimum washout of 7
days. Triplicate 12-lead electrocardiogram (ECG) mea-
surements were performed and PK samples collected
predose and at 1, 2, 3, 4, 5, 6, 9, 12, and 24 hrs post-
dose. Vital signs were measured predose, 3 hrs postdose
and at discharge. Adverse event monitoring and safety
laboratory testing were performed throughout.
Summary of results
All 48 subjects enrolled were white males (mean age
39.1 yrs, body mass index 25.6 kg/m2) and completed
the study. Following LRV administration, the upper
bound of 90% CI for time-matched adjusted mean dif-
ferences to placebo in QTcF at each of the time points
postdose was below the regulatory threshold of 10 msec,
thus satisfying the criteria for a negative thorough QT/
QTc study. The highest upper bound of 90% CI
occurred at 6 hrs for LRV (3.32, 90% CI 1.5, 5.1). The
study was deemed adequately sensitive as the lower
bound of the 90% CI for the adjusted mean differences
between moxifloxacin and placebo at moxifloxacin’s his-
torical Tmax of 3 hrs was >5 msec (15.29 msec, 90% CI:
13.5, 17.1 msec). No subjects receiving LRV or placebo
had a QTcF ≥450 msec, nor did any experience a QTcF
increase ≥30 msec from baseline at any time point. In
subjects receiving LRV, no clinically significant changes
in QRS complex, PR interval, heart rate or blood pres-
sure were observed. PK analysis of blood samples indi-
cated geometric mean (CV%) AUClast 17750 ng.hr/mL
(28%) and Cmax 1727 ng/mL (33%), and median Tmax 3
hrs. Adverse events were generally mild, with some
moderate gastrointestinal events.
Conclusions
LRV administered as a single 2400 mg supratherapeutic
dose did not prolong the QTc interval and no clinically
relevant ECG or vital sign changes were observed in
healthy subjects.
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